NEW YORK, N.Y., Oct. 4, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) a biopharmaceutical company with an internal preclinical and clinical-stage pipeline, and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that Dr. Daniel Chain, Ph.D., Chairman and CEO, will participate in the Phacilitate CNS Leaders Forum November 7-9, 2011 at the Seaport, Boston.
Dr. Chain's speech, "How can recent advances in our understanding of neurodegenerative diseases such as Alzheimer's and Parkinson's impact new clinical development strategies?" leads off a focus session entitled "Plotting a path forward to effective Phase II clinical trial design for neurodegenerative diseases." The session begins at 11:00 a.m.
The Phacilitate CNS Leaders' Forum is an event designed for senior R&D and business executives driving the development, registration and launch of novel neurology, neuropsychology and pain drugs. More than 90 high profile speakers including executive and senior level directors from Big Pharma and biotechnology industries are scheduled to participate. Dr. Chain will speak at 12.30 PM on November 7. Details of the conference may be found at www.phacilitate.co.uk/pages/leaders/cns_agenda_d1_s2.html
About Intellect Neurosciences, Inc.
Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease, and other neurodegenerative diseases, especially focused on proteinopathies. Its pipeline includes small neuroprotective molecules and neoepitope-based immunotherapy approaches, including monoclonal antibodies and vaccines targeting beta amyloid and abnormal tau proteins. Previously, Intellect Neurosciences out-licensed late-stage antibody products based on the Company's ANTISENILIN® Alzheimer's beta amyloid monoclonal antibody technology to several major pharmaceutical companies. In addition, the company recently licensed OX1, a small molecule antioxidant, to ViroPharma for Friedreich's Ataxia and other neurodegenerative diseases.
Currently, the company is focused on developing next generation antibody therapeutics. Its most advanced internal candidate is a humanized monoclonal antibody drug conjugate being developed for age-related macular degeneration and other diseases and conditions caused by beta amyloidosis.
Safe Harbor Statement Regarding Forward-Looking Statements:
The statements in this release and oral statements made by representatives of Intellect relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333-128226), filed on October 13, 2010, and information contained in our Quarterly Report on Form 10-Q for the three month period ended March 31, 2011, filed on May 23, 2011.